Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|October 17, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-11-02-2016
- Volume 11
- Issue 11
CordenPharma Completes API Process Bay
Author(s)Pharmaceutical Technology Editors
CordenPharma announced the completion of a new highly potent process bay for APIs at the company’s Colorado facility.
Advertisement
On Oct. 17, 2016, CordenPharma announced that the company has completed a recent investment to strengthen development and manufacturing capabilities for API offerings across its highly potent and oncology platform. The new API process bay, now installed in the company’s Colorado facility, is designed to handle a wide range of chemistries and unit operations with flexible and scalable components up to multi-kg batches.
This investment comes after the completion in early 2016 of a new cancer target discover and development (CTD2) facility for the development and manufacture of oral solid-dosage drug product and manufacture of highly potent and oncology compounds in its CordenPharma Plankstadt, Germany facility. The company also expanded capabilities in handling sterile oncology drug products at CordenPharma Latina, Italy.
“With the operational qualification now complete, the first cGMP campaign is scheduled to be completed in early Q4 2016,” Brian McCudden, president and managing director of CordenPharma Colorado, said in a statement. This new addition complements the existing infrastructure at CordenPharma Colorado, which is equipped to handle highly potent compounds up to OEB Level 5 spanning development to commercial-scale.
Source:
Articles in this issue
almost 10 years ago
Cost-Effective Catalysts Could Replace Traditional Multi-Step Processesalmost 10 years ago
Pharma Assesses Technologies to Prevent Fakesalmost 10 years ago
Outlook for Fill/Finish Outsourcing Stays Healthyalmost 10 years ago
A Global Fight to Protect the Drug Supplyalmost 10 years ago
Interpharm Praha A.S Receives FDA Warning Letteralmost 10 years ago
Multi-Tenant Warehouse Option Aids Healthcare Companiesalmost 10 years ago
Catalent Breaks Ground for Expanded Biologics Facilityalmost 10 years ago
NJIT Researchers Honored for API Coating Technologyalmost 10 years ago
ICH Introduces Two New Guidelinesalmost 10 years ago
Recipharm to Open New GLP Bioanalysis Laboratory in SwedenAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5